Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026, indicating non-compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). The company's American Depositary Shares (ADSs) had traded below $1.00 per share for 30 consecutive business days, triggering the notice.
The notification has no immediate impact on the listing or trading of Scinai's ADSs on the Nasdaq Capital Market. The company has been granted a 180-day compliance period, extending through September 8, 2026, to regain compliance. During this period, if the closing bid price of Scinai's ADSs meets or exceeds $1.00 per share for at least 10 consecutive business days, Nasdaq will provide written confirmation of compliance, and the matter will be resolved.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company's pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Additionally, Scinai owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical companies.
This announcement is significant as it highlights the company's current financial challenges reflected in its stock price, which may affect investor confidence. However, the 180-day grace period provides Scinai with an opportunity to take corrective actions, such as implementing a reverse stock split or other measures to boost its share price. Failure to regain compliance could eventually lead to delisting, which would have serious implications for the company's access to capital markets and liquidity.
For more details, the full press release can be accessed at https://ibn.fm/faOR5. The latest news and updates regarding SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
